423.47
price down icon2.44%   -10.60
after-market Handel nachbörslich: 423.24 -0.23 -0.05%
loading
Schlusskurs vom Vortag:
$434.07
Offen:
$429.9
24-Stunden-Volumen:
1.17M
Relative Volume:
1.01
Marktkapitalisierung:
$55.51B
Einnahmen:
$3.21B
Nettoeinkommen (Verlust:
$43.57M
KGV:
1,760.79
EPS:
0.2405
Netto-Cashflow:
$221.36M
1W Leistung:
-11.02%
1M Leistung:
-7.20%
6M Leistung:
+63.26%
1J Leistung:
+56.87%
1-Tages-Spanne:
Value
$421.83
$431.50
1-Wochen-Bereich:
Value
$421.83
$482.73
52-Wochen-Spanne:
Value
$205.87
$495.55

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Firmenname
Alnylam Pharmaceuticals Inc
Name
Telefon
(617) 551-8200
Name
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Mitarbeiter
2,230
Name
Twitter
@alnylam
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
423.47 57.35B 3.21B 43.57M 221.36M 0.2405
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
421.67 109.22B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
628.00 67.50B 14.25B 4.58B 3.88B 41.77
Biotechnology icon
ARGX
Argen X Se Adr
831.48 50.87B 3.06B 1.28B 447.35M 19.67
Biotechnology icon
INSM
Insmed Inc
182.77 39.72B 447.02M -1.18B -868.57M -6.1812

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-08-04 Hochstufung Oppenheimer Perform → Outperform
2025-08-04 Hochstufung Wolfe Research Underperform → Peer Perform
2025-07-30 Fortgesetzt Raymond James Outperform
2025-07-21 Eingeleitet Truist Buy
2025-03-31 Eingeleitet Redburn Atlantic Buy
2025-03-24 Hochstufung JP Morgan Neutral → Overweight
2024-11-12 Herabstufung Wolfe Research Peer Perform → Underperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-08-16 Hochstufung Goldman Neutral → Buy
2024-02-16 Herabstufung Goldman Buy → Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-08 Eingeleitet Wells Fargo Equal Weight
2023-10-11 Herabstufung Oppenheimer Outperform → Perform
2023-09-29 Eingeleitet Raymond James Outperform
2023-05-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-26 Eingeleitet SMBC Nikko Neutral
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Buy
2022-09-09 Fortgesetzt Morgan Stanley Equal-Weight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-27 Herabstufung Guggenheim Buy → Neutral
2022-06-07 Eingeleitet William Blair Outperform
2022-04-25 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-03-01 Eingeleitet Citigroup Buy
2022-02-03 Hochstufung Guggenheim Neutral → Buy
2022-01-03 Hochstufung Piper Sandler Neutral → Overweight
2021-11-22 Hochstufung Goldman Neutral → Buy
2021-11-22 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Hochstufung Oppenheimer Perform → Outperform
2021-10-04 Hochstufung UBS Neutral → Buy
2021-08-04 Herabstufung Piper Sandler Overweight → Neutral
2021-02-22 Herabstufung Guggenheim Buy → Neutral
2021-02-12 Herabstufung Citigroup Buy → Neutral
2021-02-12 Bestätigt H.C. Wainwright Buy
2021-01-25 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-09-30 Fortgesetzt Berenberg Hold
2020-09-08 Eingeleitet Citigroup Buy
2020-08-11 Herabstufung Oppenheimer Outperform → Perform
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2020-05-07 Herabstufung JP Morgan Overweight → Neutral
2020-04-24 Fortgesetzt Evercore ISI Outperform
2020-03-19 Eingeleitet Berenberg Buy
2019-12-19 Bestätigt Chardan Capital Markets Buy
2019-11-20 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-06 Hochstufung Evercore ISI In-line → Outperform
2019-03-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-01-23 Eingeleitet UBS Neutral
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-13 Bestätigt Stifel Buy
2018-08-07 Hochstufung Stifel Hold → Buy
2018-05-04 Bestätigt Stifel Hold
2018-03-28 Eingeleitet Evercore ISI In-line
Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

pulisher
11:28 AM

Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds - Yahoo Finance

11:28 AM
pulisher
08:24 AM

Alnylam (NASDAQ: ALNY) to present Nov 10 & Nov 19 at UBS and Jefferies; live webcasts - Stock Titan

08:24 AM
pulisher
08:00 AM

Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire

08:00 AM
pulisher
07:21 AM

Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative

07:21 AM
pulisher
06:30 AM

Hussman Strategic Advisors Inc. Sells 2,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

06:30 AM
pulisher
06:23 AM

Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stock2025 Volatility Report & Weekly High Momentum Picks - newser.com

06:23 AM
pulisher
05:35 AM

Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryInflation Watch & Low Drawdown Investment Ideas - newser.com

05:35 AM
pulisher
04:35 AM

Amalgamated Bank Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

04:35 AM
pulisher
04:19 AM

Assetmark Inc. Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

04:19 AM
pulisher
04:10 AM

Regression analysis insights on Alnylam Pharmaceuticals Inc. performancePortfolio Gains Report & Daily Risk Controlled Trade Plans - newser.com

04:10 AM
pulisher
04:09 AM

Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumWeekly Stock Report & Real-Time Sentiment Analysis - newser.com

04:09 AM
pulisher
01:53 AM

Will Alnylam Pharmaceuticals Inc. continue its uptrendMarket Activity Summary & Fast Exit/Entry Strategy Plans - newser.com

01:53 AM
pulisher
01:21 AM

Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Review & Target Return Focused Picks - newser.com

01:21 AM
pulisher
01:15 AM

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline - GlobeNewswire Inc.

01:15 AM
pulisher
Nov 03, 2025

How to monitor Alnylam Pharmaceuticals Inc. with trend dashboards2025 Price Action Summary & Weekly Chart Analysis and Trade Guides - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

What data driven models say about Alnylam Pharmaceuticals Inc.’s futureTreasury Yields & Fast Exit and Entry Trade Guides - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stock2025 Stock Rankings & Long-Term Investment Growth Plans - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Combining machine learning predictions for Alnylam Pharmaceuticals Inc.2025 Market Sentiment & Stepwise Entry and Exit Trade Signals - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Tredje AP fonden Has $3.98 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Nov 03, 2025
pulisher
Nov 03, 2025

Alnylam (ALNY) Dropped from Goldman Sachs Conviction List - GuruFocus

Nov 03, 2025
pulisher
Nov 03, 2025

How to recover losses in Alnylam Pharmaceuticals Inc. stock2025 Bull vs Bear & Comprehensive Market Scan Reports - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flowsJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Has Alnylam Pharmaceuticals Inc. found a price floorJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Sumitomo Life Insurance Co. Makes New Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Nov 03, 2025
pulisher
Nov 03, 2025

Published on: 2025-11-03 03:21:20 - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is Alnylam Pharmaceuticals Inc. stock resilient to inflationJuly 2025 Sentiment & AI Driven Stock Price Forecasts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

How dovish Fed policy supports Alnylam Pharmaceuticals Inc. (DUL) stock2025 Historical Comparison & Real-Time Stock Entry Alerts - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Envestnet Asset Management Inc. Buys 23,749 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Nov 03, 2025
pulisher
Nov 03, 2025

How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersEarnings Overview Report & Precise Buy Zone Tips - newser.com

Nov 03, 2025
pulisher
Nov 03, 2025

Is it time to cut losses on Alnylam Pharmaceuticals Inc.July 2025 Earnings & Fast Entry and Exit Trade Plans - newser.com

Nov 03, 2025
pulisher
Nov 02, 2025

Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.July 2025 Drop Watch & Stepwise Trade Execution Plans - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockOptions Play & Free Community Supported Trade Ideas - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesQuarterly Trade Summary & Community Consensus Trade Signals - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Alnylam Pharmaceuticals Hits Day Low of $436.51 Amid Price Pressure - Markets Mojo

Nov 02, 2025
pulisher
Nov 02, 2025

Alnylam Pharmaceuticals, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year - Yahoo Finance

Nov 02, 2025
pulisher
Nov 02, 2025

Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet - Benzinga

Nov 02, 2025
pulisher
Nov 02, 2025

ANTIPODES PARTNERS Ltd Sells 36,750 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikes2025 Technical Overview & High Accuracy Trade Alerts - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Strs Ohio Has $9.83 Million Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Focus Partners Advisor Solutions LLC Has $263,000 Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsJuly 2025 Review & Capital Efficiency Focused Strategies - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

What to do if you’re stuck in Alnylam Pharmaceuticals Inc.Wall Street Watch & Low Drawdown Investment Ideas - newser.com

Nov 02, 2025
pulisher
Nov 02, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Downgraded to Buy Rating by Wall Street Zen - MarketBeat

Nov 02, 2025
pulisher
Nov 02, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Q3 2025 Earnings Call Transcript - Insider Monkey

Nov 02, 2025
pulisher
Nov 02, 2025

A Fresh Look at Alnylam Pharmaceuticals (ALNY) Valuation Following Q3 Profit Surge and Upgraded Guidance - simplywall.st

Nov 02, 2025

Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Alnylam Pharmaceuticals Inc-Aktie (ALNY) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Greenstreet Yvonne
Chief Executive Officer
Oct 02 '25
Sale
452.05
8,924
4,034,085
65,409
Tanguler Tolga
EVP, Chief Commercial Officer
Oct 02 '25
Sale
452.05
1,405
635,126
27,438
Fitzgerald Kevin Joseph
CSO & EVP, Head of Research
Oct 02 '25
Sale
452.05
2,441
1,103,451
25,231
Garg Pushkal
EVP Chief R&D
Oct 03 '25
Sale
451.48
3,022
1,364,387
20,221
Garg Pushkal
EVP Chief R&D
Oct 02 '25
Sale
452.05
2,937
1,327,675
23,243
$831.48
price up icon 0.63%
$628.00
price down icon 2.22%
$182.77
price down icon 1.86%
biotechnology ONC
$309.19
price down icon 0.86%
$104.83
price up icon 0.84%
Kapitalisierung:     |  Volumen (24h):